regn5458, a bcmaxcd3 bispecific monoclonal antibody, in a phase 1/2 1st-in-human study in rrmm pts
Published 2 years ago • 571 plays • Length 7:26
Download video MP4
Download video MP3
Similar videos
-
7:18
response rate on phase 1/2 trial regn5458 (bcmaxcd3 bispecific antibody) for rrmm patients
-
7:25
updated phase 1 results of teclistamab, a bcma × cd3 bispecific antibody, in rrmm
-
9:57
teclistamab, a bcma × cd3 bispecific antibody, in pts with rrmm: updated phase 1 results
-
4:28
first-in-human study of tnb-383b, a bcma x cd3 bispecific t-cell redirecting antibody, in pts w/rrmm
-
9:41
redirectt-1 study: dual targeting of bcma and gprc5d in rrmm pts with teclistamab and talquetamab
-
7:06
efficacy and safety of elranatamab bcma-cd3 bispecific antibody, in patients with rrmm
-
4:45
a first-in-human trial of linvoseltamab (regn5458) in r/r myeloma: updated phase i data
-
2:25
current and emerging immune therapies in al amyloidosis: updates on hbi0101 & bispecifics
-
8:43
results from monumental-1: first-in-human study of talquetamab in pts with rr multiple myeloma
-
10:57
linker-mm1 study: linvoseltamab (regn5458) in patients with rr multiple myeloma | asco 2023
-
3:20
phase i trial of a bcma-cd3 bispecific antibody in r/r myeloma
-
2:50
phase i study of abbv383, a novel bcmaxcd3 bispecific antibody, in r/r multiple myeloma
-
4:26
what are bispecific antibodies?
-
4:45
bispecifics part 2: monoclonal and bispecific antibodies
-
6:58
phase 1 study of the gprc5dxcd3 bispecific talquetamab in patients with rr multiple myeloma
-
6:36
updated results of a phase 1, first-in-human study of talquetamab in relapsed refractory mm
-
3:44
phase i study of teclistamab, a humanized bcma x cd3 bispecific antibody, in relapsed/refractory mm
-
4:16
what is the monoclonal antibody talvey™ (talquetamab)?
-
1:47
linker-mm1: linvoseltamab, a bispecific antibody, in r/r multiple myeloma
Clip.africa.com - Privacy-policy